Fulminant myocarditis during postoperative adjuvant chemotherapy for lung cancer with atezolizumab: a case report

Abstract Background Postoperative adjuvant systemic therapy with atezolizumab for lung cancer has been reported to be effective. Although myocarditis is a rare immune adverse event associated with atezolizumab, it can have a serious course and should be treated with caution. We herein report a case...

Full description

Bibliographic Details
Published in:Journal of Medical Case Reports
Main Authors: Takuya Tokunaga, Masaya Aoki, Koki Maruyama, Yuto Nonaka, Kota Kariatsumari, Koichi Sakasegawa, Kazuhiro Ueda
Format: Article
Language:English
Published: BMC 2024-03-01
Subjects:
Fulminant myocarditis
Lung cancer
Adjuvant chemotherapy
Atezolizumab
Online Access:https://doi.org/10.1186/s13256-024-04447-w

Internet

https://doi.org/10.1186/s13256-024-04447-w

Similar Items